09th week of 2009 patent applcation highlights part 49 |
Patent application number | Title | Published |
20090054383 | Pharmaceutical compositions - Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed. | 2009-02-26 |
20090054384 | AIRWAY ALKALINIZATION AS THERAPY FOR AIRWAY DISEASES - The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase. | 2009-02-26 |
20090054385 | SOLID INHALATION FORMULATIONS OF DEHYDROEPIANDROSTERONE DERIVATIVES - Solid pharmaceutical compositions and kits for administration to the lungs comprise a carrier and an agent for the treatment of bronchoconstriction and asthma, wherein the agent comprises a derivative of dehydroepiandrosterone having an SO2H or SO2Na group. The solid formulations can be administered as an aerosol. | 2009-02-26 |
20090054386 | Compositions and Methods for Inducing Bone Growth and Inhibiting Bone Loss - Compositions useful for inducing bone growth or inhibiting bone loss in an animal comprising one or more isoflavones or isoflavone metabolites and methods for inducing bone growth or inhibiting bone loss in an animal utilizing such compositions. The compositions and methods are particularly useful for post-menopause, post-andropause, gonadectomized, spayed, or neutered animals. | 2009-02-26 |
20090054387 | Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benz- aldehyde (E)-oxime (asoprisnil) - The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.). | 2009-02-26 |
20090054388 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES - The invention provides 11β-hydroxyandrosta-4-ene-3-one compounds of Formula I, or physiologically acceptable salts or solvates thereof: | 2009-02-26 |
20090054389 | Topical Composition Comprising an Antibacterial Substance - A pharmaceutical composition for topical application comprises a fusidic acid derivative of general formula I as disclosed herein and one or more monoglycerides of a fatty acid. The composition may be used in the treatment of a disease or condition of the skin or mucosa, in particular skin infections. | 2009-02-26 |
20090054390 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture - This invention relates to methods for providing prognosis of a subjects susceptibility to plaque rupture and compositions for treating plaque rupture and intraplaque hemorrhage. Specifically, the invention is directed to the use of haptoglobin genotyping in determining the susceptibility of a subject to develop intraplaque hemorrhage resulting from plaque rapture and treatment of the intraplaque hemorrhage using antioxidants. | 2009-02-26 |
20090054391 | Biologically active complex - The invention relates to an aqueous solution containing at least one species selected from the group consisting of a 1:1 molar complex of TeO | 2009-02-26 |
20090054392 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM - The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog. | 2009-02-26 |
20090054393 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL - The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitade) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe). Co-administration of the MTP inhibitor with the CAI produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and/or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit. | 2009-02-26 |
20090054394 | POLYMORPHISMS IN MGST3 ARE ASSOCIATED WITH ELEVATED ALAT LEVELS AFTER XIMELAGATRAN TREATMENT - This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the MGST3 gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients. | 2009-02-26 |
20090054395 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH - The present invention relates to a compound of the formula I | 2009-02-26 |
20090054396 | SUBSTITUTED THIOPHENES AND USES THEREOF - This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer. | 2009-02-26 |
20090054397 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND - The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. | 2009-02-26 |
20090054398 | CHEMICAL COMPOUNDS - The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutically acceptable salt form or in the form of a pharmaceutically acceptable solvate of the compound or the salt, to a human or animal patient in need thereof. | 2009-02-26 |
20090054399 | HIV INTEGRASE INHIBITORS - Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R | 2009-02-26 |
20090054400 | NEW PROGESTERONE RECEPTOR MODULATORS - The present invention provides new progesterone receptor modulators which are dibenzo[b,f]pyrido[1,2-d]oxazepine-2-amines or dibenzo[b,f]prido[1,2-d]thiazepine-2-amines, and uses thereof. | 2009-02-26 |
20090054401 | Substituted bicyclic derivatives and use thereof - [Object] To provide a compound having prostaglandin production-suppressing action and leukotriene production-suppressing action.
| 2009-02-26 |
20090054402 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS - Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed. | 2009-02-26 |
20090054403 | Treatment of Post-Traumatic Stress Disorder - Provided are methods of treating a patient diagnosed with post-traumatic stress disorder, by administering to the patient a therapeutically effective amount of Compound A. Also provided are methods of improving resilience in a patient by administering a therapeutically effective amount of Compound A. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of Compound A and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the Compound A reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder. | 2009-02-26 |
20090054404 | USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN | 2009-02-26 |
20090054405 | PI3 kinase modulators and methods of use - The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula I | 2009-02-26 |
20090054406 | Compositions and Methods for Modulating Endophthalmitis Using Fluoroquinolones - Compositions for modulating endophthalmitis comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating endophthalmitis comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating post-operative endophthalmitis, post-traumatic endophthalmitis, non-infectious endophthalmitis, panophthalmitis, hematogenous endophthalmitis, or combinations thereof. | 2009-02-26 |
20090054407 | Nitrogen-containing heterocyclic compound - The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): | 2009-02-26 |
20090054408 | Monocyclic anilide spirolactam cgrp receptor antagonists - The present invention is directed to compounds of Formula I: I (where A | 2009-02-26 |
20090054409 | IMIDAZO [1,2-A] PYRIDINE HAVING ANTI-CELL-PROLIFERATION ACTIVITY - Compounds of formula (I): | 2009-02-26 |
20090054410 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for producing such substituted 1,2,4-thiadiazole derivatives. | 2009-02-26 |
20090054411 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS - The invention relates to chemical compounds of formula IA or IB: | 2009-02-26 |
20090054412 | Treatment of Sleep Disorders - A method for treating various types of insomnia is provided using 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt. | 2009-02-26 |
20090054413 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease - The present invention provides a compound of a formula (I): | 2009-02-26 |
20090054414 | Rufinamide for the Treatment of Post-Traumatic Stress Disorder - Provided are methods of treating post-traumatic stress disorder with rufinamide. Also provided are methods of treating kindling and improving resilience with rufinamide. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of rufinamide and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the rufinamide reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder. | 2009-02-26 |
20090054415 | COMBINATIONS, METHODS AND COMPOSITIONS FOR TREATING CANCER - The invention relates to a combination of BCR-ABL inhibitor, exemplified by ‘N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide and/or other BCR/ABL inhibitors, and a stem cell selective cytotoxic, exemplified by (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile, hydrochloride salt, and or other stem cell cytotoxic agents, pharmaceutical compositions of the combination and to methods of using the pharmaceutical compositions in the treatment of oncological disorders. | 2009-02-26 |
20090054416 | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide Derivatives, Preparation and Therapeutic Use Thereof - The present invention discloses and claims compounds of general formula | 2009-02-26 |
20090054417 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activation of steroid hormone nuclear receptors. | 2009-02-26 |
20090054418 | Antibacterial Agents - 2H-chromen-2-one derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein. | 2009-02-26 |
20090054419 | 3,7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE - This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R | 2009-02-26 |
20090054420 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS - Compounds of formula (I) | 2009-02-26 |
20090054421 | Pyrimidothiophene Compounds Having HSP90 Inhibitory Activity - Compounds of formula (I) are HSP90 inhibitors, of utility in the treatment of, for example, cancers: wherein R | 2009-02-26 |
20090054422 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias - There is provided compounds of formula I, wherein R | 2009-02-26 |
20090054423 | Niacin receptor agonists, compositions containing such compounds and methods of treatment - The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included. | 2009-02-26 |
20090054424 | Optically active pyridine derivative and a medicament containing the same - An optically active (−)-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one of the formula: | 2009-02-26 |
20090054425 | PROTEIN KINASE INHIBITORS - Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: | 2009-02-26 |
20090054426 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity. | 2009-02-26 |
20090054427 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS - The invention relates to novel heterocyclic compounds of the formula | 2009-02-26 |
20090054428 | NOVEL PYRIMIDINE DERIVATIVES 965 - The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof, | 2009-02-26 |
20090054429 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS - This invention provides novel arylindenopyridines and arylindenopyrimidines of the formula: | 2009-02-26 |
20090054430 | Inhibitors of Protein Kinases - Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. | 2009-02-26 |
20090054432 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors - The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed. | 2009-02-26 |
20090054433 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST - The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HT | 2009-02-26 |
20090054434 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS - The present invention is directed to certain isoquinolin-1(2H)-one compounds, useful as PDE10 inhibitors, having the formula: | 2009-02-26 |
20090054435 | Phenoxyalkanoic Acid Compound - The present invention provides a compound represented by the formula: | 2009-02-26 |
20090054436 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS - The present invention is directed to compounds having the formula | 2009-02-26 |
20090054437 | Nitrocatechol Derivatives as Comt Inhibitors - New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders. | 2009-02-26 |
20090054438 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA - There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof. | 2009-02-26 |
20090054439 | SULFONAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF - The present invention is directed to a compound of formula (I): | 2009-02-26 |
20090054440 | Quinoline derivatives as neurokinin receptor antagonists - The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R | 2009-02-26 |
20090054441 | Process For The Preparation of an Optically Active 5H-Pyrrolo [3,4-B] Pyrazine Derivative - A substantially pure dextrorotatory isomer of zopiclone or a pharmaceutically acceptable salt thereof and crystalline forms thereof are provided. Also provided is a process for its preparation and pharmaceutical compositions containing same. | 2009-02-26 |
20090054442 | METHOD OF ADMINISTERING OPHTHALMIC FLUIDS - A method is provided of treating an eye with ophthalmologically active compounds, particularly with intra-ocular pressure lowering (IOP) compounds, where a dose of 5-15 microliters is delivered at a standard concentration. | 2009-02-26 |
20090054443 | COMPOSITIONS CONTAINING RIBOFLAVIN AND SESAMIN-CLASS COMPOUNDS - The present invention relates to a composition containing riboflavin and a sesamin-class compound(s). This composition may incorporate a sesamin-class compound(s) in such an amount that the proportion (weight ratio) of its total quantity to the total quantity of riboflavin taken as unity is no more than 4.5, and it has the advantage that the analgesic and anti-fatigue actions of riboflavin are synergistically improved by ingestion of riboflavin in combination with a sesamin-class compound(s). | 2009-02-26 |
20090054444 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS - Compounds of Formula (I) wherein R | 2009-02-26 |
20090054445 | Amide Substituted Quinolines - Compounds of Formula I | 2009-02-26 |
20090054446 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS - The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, | 2009-02-26 |
20090054447 | 2,3 Substituted Pyrazine Sulfonamides as Inhibitors of CRTH2 - The present invention is related to the use of 2,3 substituted pyrazine sulfonamides of formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of 2,3 substituted pyrazine sulfonamides for the modulation, notably the inhibition, of CRTH2 activity. | 2009-02-26 |
20090054448 | Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors - The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or stereoisomers thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases. | 2009-02-26 |
20090054449 | Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands - The invention relates to substituted N-heterocyclic compounds of general formula (I.A) | 2009-02-26 |
20090054450 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS - Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors. | 2009-02-26 |
20090054451 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity - The present invention is directed to novel piperidine derivatives and to the use of piperidine derivatives of formula I | 2009-02-26 |
20090054452 | Thienopyridine Derivatives and the Use Thereof as Hsp90 Modulators - Novel thienopyridine derivatives of the formula (I), in which R | 2009-02-26 |
20090054453 | Novel Tetralins as 5-HT6 Modulators - The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, wherein Q, R | 2009-02-26 |
20090054454 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE - Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed. | 2009-02-26 |
20090054455 | ARIPIPRAZOLE CO-CRYSTALS - Co-crystals comprising aripiprazole and fumaric acid. | 2009-02-26 |
20090054456 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE - The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders. | 2009-02-26 |
20090054457 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I: | 2009-02-26 |
20090054458 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE - The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments. | 2009-02-26 |
20090054459 | Substituted indoles - Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R | 2009-02-26 |
20090054460 | Piperazine derivatives and methods of use - Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2009-02-26 |
20090054461 | PHARMACEUTICAL COMPOSITION COMPRISING A 1-(3-CHLOROPHENYL)-3-ALKYLPIPERAZINE FOR TREATING APETITE DISORDER -
Use of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I), in racemic (R, S) form or in the form of the (S) enantiomer, in which R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, for treating apetite disorder A pharmaceutical composition that comprises a therapeutically effective amount of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I) as previously defined or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, and at least one pharmaceutically acceptable excipient. | 2009-02-26 |
20090054462 | Hydroisoindoline tachykinin receptor antagonists - The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety. | 2009-02-26 |
20090054463 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor - The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes. | 2009-02-26 |
20090054464 | HDAC INHIBITOR - Compounds having the formula (I): | 2009-02-26 |
20090054465 | N-HYDROXYACRYLAMIDE COMPOUNDS - This invention relates to novel N-hydroxyacrylamide compounds of formula (I) and pharmaceutically acceptable salts thereof. More particularly, it relates to novel N-hydroxyacrylamide compounds and pharmaceutically acceptable salts thereof which act as a HDAC inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of HDAC-related disease. | 2009-02-26 |
20090054466 | Leukotriene B4 Inhibitors - Provided herein are compounds of the formula (I): | 2009-02-26 |
20090054467 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases - The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. | 2009-02-26 |
20090054468 | New Use 938 - The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection. | 2009-02-26 |
20090054469 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS - The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man. | 2009-02-26 |
20090054470 | USE OF MITOCHONDRIAL ELECTRON TRANSPORT INHIBITORS TO CONTROL FOULING ORGANISMS - The present invention relates to the use of mitochondrial electron transport inhibitors (METI's) to control or combat fouling organisms. More particularly, the present invention relates to the use of mitochondrial electron transport inhibitors for protecting materials against fouling by marine or freshwater fouling organisms and an antifouling composition suitable for use therefore. This invention thus relates to the field of protection of materials that are exposed to humid or aqueous environments. | 2009-02-26 |
20090054471 | PYRIDOPYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USES AS ANTI-CANCER AND ANTI-DIABETE DRUGS - The present invention relates to pyridopyrazolopyrimidine derivatives that are useful pharmacological agents through the inhibition or antagonism of protein kinases, and to processes for the preparation and use of the same. In particular, the present invention relates to compounds that demonstrate protein tyrosine kinase and/or protein serine/threonine kinase inhibition. | 2009-02-26 |
20090054472 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof - A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth. | 2009-02-26 |
20090054473 | THERAPY FOR COMPLICATIONS OF DIABETES - A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET | 2009-02-26 |
20090054474 | Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same - A compound represented by the following general formula (I) or a salt thereof, or a solvate thereof: | 2009-02-26 |
20090054475 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS - Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active. | 2009-02-26 |
20090054476 | A3 Adenosine receptor allosteric modulators - The present invention relates to allosteric modulation of A | 2009-02-26 |
20090054477 | 4-thio substituted quinoline and naphthyridine compounds - The present invention relates to 4-thio substituted quinoline and naphthyridine derivatives and processes for their preparation. The invention also related to methods for treating infection of Hepatitis C virus by administering a 4-thio substituted quinoline or naphthyridine derivative. | 2009-02-26 |
20090054478 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The present invention relates to azolopyridin-3-one derivatives of the general formula I with the meanings indicated in the description, their pharmaceutically usable salts and their use as medicinal substances. | 2009-02-26 |
20090054479 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS - The present invention is directed to compounds represented by the following structural formula, Formula I: | 2009-02-26 |
20090054480 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors. | 2009-02-26 |
20090054481 | Saquinavir Mesylate Oral Dosage Form - A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight. | 2009-02-26 |
20090054482 | Method of making and administering quinoline derivatives as anti-cancer agents - The present invention relates methods of preparing quinoline derivative compounds, and administering such compounds in the treatment of solid and non-solid tumors, notably on liver cancer. | 2009-02-26 |
20090054483 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis - The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents. | 2009-02-26 |